Risk factors for colistin-resistant Enterobacteriaceae in a low-endemicity setting for carbapenem resistance - a matched case-control study

被引:19
作者
Buchler, Andrea C. [1 ]
Gehringer, Christian [2 ,3 ]
Widmer, Andreas F. [1 ]
Egli, Adrian [3 ,4 ]
Tschudin-Sutter, Sarah [1 ,5 ]
机构
[1] Univ Basel, Univ Basel Hosp, Div Infect Dis & Hosp Epidemiol, Basel, Switzerland
[2] Univ Basel, Univ Basel Hosp, Div Internal Med, Basel, Switzerland
[3] Univ Basel, Univ Basel Hosp, Div Clin Microbiol, Basel, Switzerland
[4] Univ Basel, Dept Biomed, Appl Microbiol Res, Basel, Switzerland
[5] Univ Basel, Univ Basel Hosp, Dept Clin Res, Basel, Switzerland
来源
EUROSURVEILLANCE | 2018年 / 23卷 / 30期
关键词
ESCHERICHIA-COLI; ACQUISITION; PREVALENCE; BACTERIA; MCR-1; GENE;
D O I
10.2807/1560-7917.ES.2018.23.30.1700777
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Emergence of colistin resistance has been related to increased use in clinical settings, following global spread of carbapenem-resistant Gram-negative bacteria. Use of colistin in animal production may constitute a further source of spread of resistant strains to humans. We sought to determine risk factors for human colonisation or infection with colistin-resistant Escherichia coli and Klebsiella pneumoniae in a setting where colistin is mainly used for animal production. Methods: This retrospective matched case-control study was performed during a 5-year period at two university-affiliated hospitals in Basel, Switzerland. Conditional univariable logistic regression was used to calculate odds ratios (OR) for colistin resistance. All variables found to be significant in univariable analyses were included in the conditional multivariable regression model using stepwise forward and backward selection. Results: Forty-two cases (33 with colistin-resistant E. coli, 9 with colistin-resistant K. pneumoniae) and 126 matched controls were identified. Baseline characteristics, comorbidities, prior exposure to antibiotics and healthcare settings did not differ between cases and controls, except for prior exposure to carbapenems, hospitalisation and stay abroad during the prior 3 months. In multivariable analyses, only prior exposure to carbapenems remained associated with colistin resistance (OR: 5.00; 95% confidence interval (95% CI): 1.19-20.92; p = 0.028). Conclusion: In a low-endemicity setting for carbapenem resistance, prior exposure to carbapenems was the only risk factor for colonisation or infection with colistin-resistant E. coli or K. pneumoniae. Prior exposure to colistin was not significantly associated with detection of colistin resistance, which mainly occurred in the absence of concurrent carbapenem resistance.
引用
收藏
页数:8
相关论文
共 30 条
  • [1] [Anonymous], 2016, LANG ENV STAT COMP
  • [2] [Anonymous], 2015, Pharmacovigilance
  • [3] Arjun R, 2017, INDIAN J CRIT CARE M, V21, P317, DOI 10.4103/ijccm.IJCCM_454_16
  • [4] Centers for Disease Control (CDC)/National Healthcare Safety Network (NHSN), 2017, CDC NHSN SURV DEF SP
  • [5] Chew KL, 2017, J CLIN MICROBIOL, V55, P2609, DOI [10.1128/JCM.00268-17, 10.1128/jcm.00268-17]
  • [6] Comparative Evaluation of Colistin Susceptibility Testing Methods among Carbapenem-Nonsusceptible Kiebsiella pneumoniae and Acinetobacter baumannii Clinical Isolates
    Dafopoulou, Konstantina
    Zarkotou, Olympia
    Dimitroulia, Evangelia
    Hadjichristodoulou, Christos
    Gennimata, Vasiliki
    Pournaras, Spyros
    Tsakris, Athanasios
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (08) : 4625 - 4630
  • [7] EUCAST The European Committee on Antimicrobial Susceptibility Testing, 2017, BREAKP TABL INT MICS
  • [8] European Committee on Antimicrobial Susceptibility Testing (EUCAST), ANT SUSC TEST COL PR
  • [9] ECDC/EFSA/EMA second joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals: Joint Interagency Antimicrobial Consumption and Resistance Analysis (JIACRA) Report
    European Centre for Disease Prevention and Control , European Food Safety Authority , European Medicines Agency
    [J]. EFSA JOURNAL, 2017, 15 (07)
  • [10] Federal Office of Public Health (FOPH), 2015, ARCH VET BER VERTR A